News Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance Insilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates.
News MSD steps out with Protillion in $510m+ AI shindig MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery
News Lilly strikes $1.9bn kidney disease alliance with Ascidian In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
News Innovent in line for $10.5bn in Pfizer cancer alliance Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.
News Newel Health, Gerresheimer team up to help pharma embrace di... Newel Health and Gerresheimer ally to help pharma firms embed digital endpoints, real-world data, and AI into clinical testing and commercialisation.
News Tuneable peptide biotech Parabilis files IPO Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.
News Despite study bust, Vistagen still hopes to file anxiety dru... Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.